Navigation Links
Safety and Efficacy of OrbusNeich's Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
Date:1/10/2011

d that the Genous Stent, which accelerates the natural healing process, enables a shorter post-procedural period of DAPT without increasing the risk of late or very late stent thrombosis and without causing dangerous delays for patients who require non-cardiac surgery shortly after PCI."

The single-center study investigated 61 high-risk patients with a clear contraindication to prolonged DAPT. A high-risk condition was defined as meeting at least two of the following criteria: diabetes, acute coronary syndrome, heart failure, proximal vessel disease, multivessel disease, B2/C type lesions, bifurcating lesions and long lesions.  The study's primary outcome measures were the occurrences of death, MI, target vessel revascularization (TVR), target lesion revascularization (TLR) and MACE, defined as a non-hierarchical composite of all cause death, nonfatal MI or repeat revascularization.

"This study adds to the growing body of knowledge published in peer-reviewed biomedical publications that supports the use of Genous for the treatment of challenging coronary indications," said Stephen M. Rowland, Ph.D., vice president of research and development at OrbusNeich. "We see in this case that high-risk patients with confounding co-morbidities precluding the use of DES still have an option that is safe and effective in the long-term."

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which  has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug-eluting ste
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 Sequent ... on developing innovative devices for the treatment of ... Kleine has joined its Board of Directors. ... years of medical device and healthcare industries experience. ... where he has commercialized numerous leading-edge products.  His ...
(Date:7/7/2015)... , July 7, 2015 Accelovance, ... focusing in Oncology, Vaccines, and General Medicine announced ... final locked database to Heron Therapeutics, Inc. for ... receptor antagonist product candidate SUSTOL® (granisetron injection, ... with the IV NK 1 receptor antagonist ...
(Date:7/7/2015)... Arentz Law Group is currently investigating cases of birth defects ... have taken Zyban while pregnant, and given birth to a ... the law firm immediately for a free legal consultation ... American Journal of Obstetrics & Gynecology  showed that mothers who ... birth to a child with " left outflow tract heart ...
Breaking Medicine Technology:Sequent Medical Appoints Mike Kleine to its Board of Directors 2Sequent Medical Appoints Mike Kleine to its Board of Directors 3Accelovance Completes Trial Enrollment and Delivery of Clinical Data for Heron Therapeutics' Phase 3 Trial 2Smoking cessation drug linked to birth defects when taken during pregnancy 2
(Date:7/7/2015)... ... July 07, 2015 , ... Illinois cannabis cultivation centers and ... permit holders. The Medical Cannabis Alliance of Illinois’ (MCAI) board and its members ... committed to making sure patients have access to cannabis as a viable medical ...
(Date:7/7/2015)... ... July 07, 2015 , ... Catalent, ... development solutions for drugs, biologics and consumer health products, today announced that ... its antibody combination therapy (ACT) technology platform. The platform has the potential ...
(Date:7/7/2015)... ... ... Safe Catch is setting revolutionary purity limits for canned tuna as the ... Community Markets, Sprouts Farmers Market and Wegmans are some of the first grocers to ... for mercury,” said Safe Catch co-founder Sean Wittenberg. “We launched Safe Catch tuna for ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Immune ... for its patient community using its IDF ePHR, an electronic personal health record ... diseases (PI) to easily track their health information, including symptoms, diagnoses, medications, infusions ...
(Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, 2015, ... the Manistee Golf and Country Club. Best Drug Rehabilitation staff members were delighted to ... helping underprivileged children. Kiwanis International, the parent of the Manistee Kiwanis Club, is a ...
Breaking Medicine News(10 mins):Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Safe Catch Launches Tuna with Lowest Mercury Limit of Any Brand 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2
... research, on laboratory animals, the curry spice turmeric ... the intestines. The spice contains curcumin, a compound ... in wound healing. ,Dr. Ken Sugimoto, of the ... //School of Medicine, Japan, showed that curcumin can ...
... boys with anorexia can develop debilitated bones as a ... anorexic boys, like girls with the disorder, can "catch-up" ... to normal weights.// , Dr. Josefina Castro of ... a relatively short duration of anorexic disorder can already ...
... researchers at the University of Texas, a new study ... a way that increases their risk of heart disease. ... and emotionally stressful tasks,// having previously assessed their level ... students were more likely to respond with a blood ...
... suspending a rule that lets the government require safety testing ... has drawn the ire of some Democratic lawmakers. FDA says ... studies. The FDA said it wants to see if the ... unnecessary.// ,But three Democrats complained to President Bush ...
... has been quite popular in recent years. But this therapy ... to cure that pain in your neck may be a ... of therapy is comparatively better to exercise therapy or treatment// ... a common problem, affecting 10 percent to 15 percent of ...
... to a new study, researchers, suggest that, some ... be prone to have children with certain chromosomal ... itself a risk factor for these types of ... of pregnancy--well before gestational diabetes typically develops.// ...
Cached Medicine News:Health News:Anorexia in boys is common too 2Health News:Gestational Diabetes linked to Chromosomal defici 2
... in less than an hour with the Obagi ... superficial procedures, the Obagi Blue Peel puts control ... your patients' particular skin needs, you determine the ... and number of coats applied. A blue mixing ...
... only, medium-depth chemical peel. ... corrext for less pain ... revolutionary medical strength peel ... facilitate a deeper penetration ...
... (TCA) peels are often thought of as ... Professional™ TCA peels are very different from ... formulated with many ingredients including lactic acid, ... kojic and azelaic acids to produce dramatic ...
... Lactic Acid is a non-irritating rapid exfoliator. ... are new to peel and exfoliating agents in ... have used other exfoliators for a long period ... a naturally occurring human metabolite, and combined with ...
Medicine Products: